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VINDESINE (desacetylvinblastine amide)
is a semisynthetic derivative of the Vinca
alkaloid group that may be prepared from
vinblastine or desacetylvinblastine (Bar-
nett et al., 1978). As a result ofits activity
against a range of experimental tumours,
the alkaloid has been introduced into the
clinic, where useful therapeutic results
have been obtained; its clinical toxicity
includes both neurological impairment of
the type seen during treatment with vin-
cristine, and marrow depression like that
produced by vinblastine (Dyke & Nelson,
1977). The pharmacokinetic pattern of
vindesine in humans closely resembles that
of vinblastine, and both are cleared more
rapidly than vincristine (Owellen et al.,
1977). Vindesine interacts with tubulin
and inhibits its polymerization (Owellen
et al., 1976), but no studies have yet been
made to determine whether the drug
interferes with the other biochemical path-
ways known to be affected by vinblastine,
vincristine and vinleurosine (Creasey,
1979). The present study demonstrates
that vindesine does indeed have the capa-
city to inhibit major biochemical path-
ways.
Sarcoma 180 (S180) cells in the ascites
form were maintained in adult Swiss mice
(CD-1) and harvested 4-6 days after i.p.
inoculation. Erythrocytes were lysed with
hypotonic saline and the washed tumour
cells resuspended in Krebs phosphate
buffer (containing in 125 ml: 0-86 g NaCl;
0-046 g KCI; 0 0073 g CaC12; 0-076 g
MgSO4.7 H20; 0 286 g NaH2PO4; 0 32 ml
IM HCI to give pH 7.4) with 12% dialysed
foetal calf serum (serum-buffer). Cell sus-
pensions (-. 2 x 107 cells) were incubated
with various concentrations of vindesine
in a final volume of 4 ml of serum-buffer
for 15 min at 37°C. Labelled precursors
were then added to study their incorpora-
tion into nucleic acids, residual proteins
and lipids (1 pCi methyl [3H]-thymidine,
3 Ci/mmol; 1 jtCi [5-3H] cytidine, 27 6 Ci/
mmol; 1 HCi [U-14C] phenylalanine, 424
mCi/mmol; 2-5 ,uCi [1,2-14C] acetate, 54
tCi/mmol). In all experiments, incubation
times were 30 min and 1 h. Oxidation of
[U-14C] glucose (0.05 ,tCi; 7-8 mCi/mmol)
was studied by incubating cells with the
tracer in a final volume of 3 ml serum-
buffer in Warburg flasks. Reactions were
stopped by tipping in perchloric acid
(0-3 ml 1M) from the side arm, and 14CO2
released during the incubation was col-
lected on filter paper moistened with
0-1 ml of IM NaOH in the centre well.
These procedures have been described in
detail in earlier publications (Creasey,
1969, 1976; Creasey & Markiw, 1965). The
collected data in the figure indicate that at
the higher concentrations of vindesine all
the parameters examined were inhibited.
Below 0a1 tM, the incorporation ofphenyl-
alanine into proteins, of acetate into
lipids and of cytidine into RNA was
elevated above the control. Inhibition of
the incorporation of [3H]dT into DNA
was manifested at a lower drug level (0-02
VuM) than for the other pathways. At
0-05 /LM and above, oxidation of glucose
to 14CO2 and the rate of DNA synthesis
followed a very similar course. The dataW. A. CREASEY
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suggest that, whilst a direct
drug may occur on DNA synt
levels, much of the inhibition
other parameters at higher co
may be nonspecific, and ascri
effect on glucose oxidation. I
cetrain respiratory processes has been
reportedforother Vincaalkaloids (Hunter,
1963; Obrecht & Fusenig, 1966), but in
the S180 tumour we found that neither
vincristine nor vinblastine (at concentra-
tions below 0-3 ,uM) inhibited the oxida-
tion of glucose to CO2. Comparison at the
2 highest drug levels indicated that
vindesine generally gave greater inhibition
of 3 selected biochemical parameters than
did vincristine or vinblastine, though the
latter produced a greater effect on RNA
synthesis (Table). The rate of agglutina-
tion of tumour cells by concanavalin A
(25 ,ug/ml) was measured spectrophoto-
metrically (Murphree et at., 1976). While
the rate of agglutination was enhanced by
43%, the lag phase before agglutination
began was reduced by an average 30%
when vindesine was present at concentra-
tions of 002-0-2 p,M. In a comparative
experiment with vincristine, the corres-
", ponding figures were 46 and 25% res-
015 pectively. Thus the 2 drugs were essenti-
ally equivalent.
oiochemical Mice bearing S180 ascites cells were
ndesine in given vindesine (2 mg/kg) by i.p. injection
nto DNA; 5 days after tumour implantation. After
; 0- 0, 1, 6 and 24 h, the animals, together with
'z, [14C] others not receiving vindesine, were in-
from both jected with 4pCi of [3H]dT, [3H] cytidine,
4 separate [14C] phenylalanine or [14C] acetate of the
specific activities and labelled positions
described above. A period of 30 min was
effect of the allowed for metabolic utilization and the
thesis at low mice were killed. Ascitic fluids were with-
of this and drawn, red cells lysed, and the tumour
ncentrations cells washed with cold 5% trichloracetic
ibable to an acid for all except acetate uptake, when
Inhibition of ethanol-ether (3:1) was used on the cell
TABLE.-Comparison ofthe effects ofvincristine, vinblastine, and vindesine on biochemical
pathways in vitro
Percent of control value at indicated concentration (/AM)
I A_
Pathway
Cytidine -+RNA
Thymidine-+DNA
Acetate -+lipid
Vincristine Vinblastine Vindesine
0-2 0.5 0-2 0.5 0-2 0.5
950 730
83-5 71 0
73-8 34-4
63-5 16-4 72*1 44.9
92-1 75-4 55 0 24-8
78-1 25-2 22-6 5-4
Incubation times were 30 min and 1 h. Results were calculated for both
intervals for 4 experiments and averaged.
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pellet. Further work-up by hot perchloric-
acid extraction, or extraction with organic
solvents for lipids, was as described above.
Data were standardized on DNA content
estimated by the diphenylamine reaction
(Burton, 1956). Only in the case of the
incorporation of [3H]dT into DNA did
vindesine produce a large depression (mean
inhibitions: 25 + 3400 at 1 h, 47 + 9.6% at
6 h and 36 + 855% at 24 h, for 6 mice per
group). Incorporation of acetate into
phospholipid was reduced by 19% at 6 h
and 14% at 24 h, while synthesis of
neutral lipid, separated on silica gel, was
markedly raised (by up to 140%). This
small but reproducible effect (s.e. + 4.50o
in 5 experiments at 24 h) is consistent with
other reports of a selective inhibition of
phospholipid synthesis by vincristine
(Creasey, 1975; Graff et al., 1967; Krowke
et al., 1970). Incorporation of precursors
into protein and RNA was not affected
significantly, in contrast to treatment with
vincristine which inhibited protein and
RNA synthesis by 58 and 3400 respect-
ively at 24 h; 6h values were almost
identical. Vinblastine exerted smaller, less
reproducible effects than vincristine. The
latter drug is known to have significantly
longer half-lives in the body than either
vinblastine or vindesine, and thus is likely
to have greater biochemical effects.
Levels of vindesine were determined by
radioimmunoassay (Root et al., 1975) in
ascitic fluid (separated from cells) over a
period between 10 min and 6 h after drug
injection. Mean values (3 mice per point)
fell from an initial maximum of 0-32 MM
to 0 025 at 1 h and 0-001 at 6 h. Only
during the first hour, therefore, were
vindesine levels in the range required to
inhibit biochemical pathways in vitro,
with inhibitory concentrations persisting
longest in the case of incorporation of
[3H]dT into DNA. Presumably there is
prolonged persistence of drug within the
tumour cells, enabling inhibition to be
maintained for 24 h.
Thus, vindesine also exerts the bio-
chemical interventions previously de-
scribed for the other Vinca alkaloids, and
indeed, may be a more effective inhibitor
under the in vitro conditions used here.
DNA synthesis is most sensitive to lower
vindesine concentrations, and is the only
process affected significantly both in vivo
and in vitro. Suppression of the oxidation
ofglucose may be a factor in the relatively
nonspecific inhibition seen at higher dose
levels in vitro. Despite these apparently
more potent actions in vitro, vindesine is
less effective as a metabolic inhibitor than
the other 2 alkaloids in vivo, a finding
compatible both with the smaller anti-
tumour effect on S180 seen during develop-
ment of this drug (Eli Lilly & Co., 1975)
and with a comparison made in our own
laboratory, where vindesine produced a
maximum increase in lifespan of 106%
compared with 186% for vinblastine at
0-25 mg/kg/day for 6 days. Pharmaco-
kinetic differences may be responsible for
this difference. Further studies of the
relation ofthe effect on glucose metabolism
to other aspects of vindesine action are
warranted, since the sensitivity of this
process appears to be unique to this
alkaloid among the V;inca group. These
will be undertaken in the P388 tumour,
which behaves similarly to 8180, because
ofrecent problems with carrying the latter
neoplasm in mice.
Thlis -work vas supporte(d by Grants (CA 14489,
16520 an(l 23147) from the United States P:ubli(
Health Service and from Eli Lilly and Company,
Indianapolis, Incliana. Ms Winifred W1eiss an(l Miss
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